title: Development of a microarray-based assay for rapid monitoring of genetic variants of West Nile virus circulating in the United States.
abstract: West Nile virus (WNV) has become endemic in the Western Hemisphere since its first introduction in the United States in 1999. An important factor associated with annual reoccurrence of WNV outbreaks in the U.S. is viral adaptation to domestic mosquitoes and birds through accumulation of spontaneous mutations in the WNV genome. Newly emerged mutations in the viral genome can potentially negatively affect the performance of existing diagnostic and screening assays and future vaccines. Therefore, the genetic monitoring of the WNV viral population during annual outbreaks is extremely important for public health and can only be achieved by application of efficient sample preparation methods followed by high throughput genetic analysis. In this study, we developed and evaluated a method for specific isolation of WNV genomic RNA from plasma samples without cultivation of the virus in cells. In combination with the microarray-based genetic analysis of the isolated WNV genomic RNA, this approach is suitable for fast, high throughput genotyping of circulating WNV genetic variants. The methods were evaluated using WNV isolates from the 1999-2012U.S. epidemics.
authors: Laboratory of Emerging Pathogens (LEP), Division of Emerging and Transfusion Transmitted Diseases (DETTD), Office of Blood Research and Review (OBRR), Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD, United States. Electronic address: Andriyan.Grinev@fda.hhs.gov.
authors: Andriyan
authors: A
authors: Grinev
authors: Laboratory of Emerging Pathogens (LEP), Division of Emerging and Transfusion Transmitted Diseases (DETTD), Office of Blood Research and Review (OBRR), Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD, United States.
authors: Caren
authors: C
authors: Chancey
authors: Laboratory of Emerging Pathogens (LEP), Division of Emerging and Transfusion Transmitted Diseases (DETTD), Office of Blood Research and Review (OBRR), Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD, United States.
authors: Evgeniya
authors: E
authors: Volkova
authors: Laboratory of Method Development (LMD), Division of Viral Products (DVP), Office of Vaccine Research and Review (OVRR), CBER, FDA, Silver Spring, MD, United States.
authors: Vladimir
authors: V
authors: Chizhikov
authors: Laboratory of Emerging Pathogens (LEP), Division of Emerging and Transfusion Transmitted Diseases (DETTD), Office of Blood Research and Review (OBRR), Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD, United States. Electronic address: Maria.Rios@fda.hhs.gov.
authors: Maria
authors: M
authors: Rios
mesh_terms: D000818:Animals; D001717:Birds / Q000821:virology; D009033:Culicidae / Q000821:virology; D058872:Epidemics; D014644:Genetic Variation; D016679:Genome, Viral; D005838:Genotype; D046228:Microarray Analysis / Q000379:methods*; D009154:Mutation; D012367:RNA, Viral / Q000097:blood* / Q000235:genetics / Q000302:isolation & purification*; D014481:United States / Q000453:epidemiology; D014901:West Nile Fever / Q000453:epidemiology / Q000821:virology; D014902:West Nile virus / Q000235:genetics* / Q000302:isolation & purification
chemical_list: D012367:RNA, Viral
keywords: Flavivirus; Genetic variability; Microarray technology; Mutations; Viral RNA isolation; West Nile virus